RSS

chimeric antigen receptor T cell (CAR-T)

GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry. more

Analysis

Edison Investment Research, has released an independent and detailed analyst report into T-cell cancer therapies, highlighting the potential and limitations of current CAR-T approaches for most tumour types. more

Analysis

Clinical-stage biopharmaceutical company, Autolus, has secured $80 million in series C financing, which it will use to establish clinical proof of concept for three novel haematological cancer programmes. more

News

Clinical-stage, biopharmaceutical start-up company, Autolus, steps into the chimeric antigen receptor (CAR)-T cell therapy fray with three new studies looking at the treatment of various cancers. more

News

Clinical-stage biopharmaceutical company, Cellectis, has received a notice from the US Food and Drug Administration (FDA) that a clinical hold has been placed on its ongoing Phase I studies evaluating the CAR-T therapy (UCART123) after a fatality. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Novartis has received approval for its chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, from the US Food and Drug Administration (FDA). more

News

The FDA has granted breakthrough therapy designation to Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019 more

News